{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Travoprost",
    "query": {
      "intervention": "Travoprost"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 54,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Travoprost&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T21:39:26.254Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04360174",
      "title": "CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "OTX-TIC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ocular Therapeutix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2018-04-25",
      "completion_date": "2021-05-24",
      "has_results": true,
      "last_update_posted_date": "2024-10-01",
      "last_synced_at": "2026-09-02T21:39:26.254Z",
      "location_count": 5,
      "location_summary": "Petaluma, California • Torrance, California • Roswell, Georgia + 2 more",
      "locations": [
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Roswell",
          "state": "Georgia"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Racine",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04360174"
    },
    {
      "nct_id": "NCT00051168",
      "title": "A Long-term Safety Study of Once-daily Travatan",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma, Open-angle",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Travatan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 502,
      "start_date": "2006-01",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2011-10-07",
      "last_synced_at": "2026-09-02T21:39:26.254Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00051168"
    },
    {
      "nct_id": "NCT00527501",
      "title": "IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Open-angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Travoprost/brinzolamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 136,
      "start_date": "2007-08",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2012-04-16",
      "last_synced_at": "2026-09-02T21:39:26.254Z",
      "location_count": 1,
      "location_summary": "Artesia, California",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00527501"
    },
    {
      "nct_id": "NCT02371746",
      "title": "Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma and Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "ENV515-3 Travoprost XR",
          "type": "DRUG"
        },
        {
          "name": "ENV515-1 Travoprost XR",
          "type": "DRUG"
        },
        {
          "name": "ENV515-3-2 Travoprost XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Envisia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 41,
      "start_date": "2015-01-01",
      "completion_date": "2019-02-13",
      "has_results": true,
      "last_update_posted_date": "2019-10-17",
      "last_synced_at": "2026-09-02T21:39:26.254Z",
      "location_count": 14,
      "location_summary": "Chandler, Arizona • Garden Grove, California • Inglewood, California + 11 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Redding",
          "state": "California"
        },
        {
          "city": "Morrow",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02371746"
    },
    {
      "nct_id": "NCT00051155",
      "title": "A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma, Open-Angle",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Travoprost (0.004%)",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost (0.005%)/Timolol (0.5%)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-01",
      "completion_date": "2004-07",
      "has_results": false,
      "last_update_posted_date": "2008-08-05",
      "last_synced_at": "2026-09-02T21:39:26.254Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00051155"
    },
    {
      "nct_id": "NCT07495852",
      "title": "Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Gen 2 Travoprost Intracameral Implant",
          "type": "DRUG"
        },
        {
          "name": "Timolol eye drops 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "placebo eye drops",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Glaukos Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 510,
      "start_date": "2026-02-17",
      "completion_date": "2032-03",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-09-02T21:39:26.254Z",
      "location_count": 1,
      "location_summary": "Dothan, Alabama",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07495852"
    },
    {
      "nct_id": "NCT00716742",
      "title": "Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Open-Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1099,
      "start_date": "2004-09",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2012-01-06",
      "last_synced_at": "2026-09-02T21:39:26.254Z",
      "location_count": 1,
      "location_summary": "Murfreesboro, Tennessee",
      "locations": [
        {
          "city": "Murfreesboro",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00716742"
    },
    {
      "nct_id": "NCT03519386",
      "title": "Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma, Open-Angle",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "G2-TR intraocular implant containing travoprost",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Sham surgery + active-comparator eye drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Glaukos Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 590,
      "start_date": "2018-07-26",
      "completion_date": "2024-04-02",
      "has_results": true,
      "last_update_posted_date": "2024-11-29",
      "last_synced_at": "2026-09-02T21:39:26.254Z",
      "location_count": 1,
      "location_summary": "Sioux Falls, South Dakota",
      "locations": [
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03519386"
    },
    {
      "nct_id": "NCT04962009",
      "title": "Safety and Intraocular Lowering Effect of Delivery of Travoprost Evolute® in Subjects With Elevated Intraocular Pressure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [],
      "conditions": [
        "Elevated Intraocular Pressure (IOP)"
      ],
      "interventions": [
        {
          "name": "Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Mati Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2021-09-08",
      "completion_date": "2022-07-15",
      "has_results": true,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-09-02T21:39:26.254Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04962009"
    },
    {
      "nct_id": "NCT00061503",
      "title": "Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Travoprost",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-04",
      "completion_date": "2004-03",
      "has_results": false,
      "last_update_posted_date": "2008-08-05",
      "last_synced_at": "2026-09-02T21:39:26.254Z",
      "location_count": 1,
      "location_summary": "Call For Details, Nebraska",
      "locations": [
        {
          "city": "Call For Details",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00061503"
    }
  ]
}